close

Agreements

1 225 226 227 228 229 230
Number of results: 4585

Excel print is not allowed for data more than 3000.Please search above for fewer data.

Date Company Compound Disease Type of agreement Therapeutic area Type of Information
2011-02-22 Pronota (Belgium) Molecuence Corporation (Japan) protein biomarkers stroke

R&D

Cerebrovascular diseases R&D agreement
2011-02-21 Sanofi Pasteur (France) International Vaccine Institute dengue fever

collaboration

Infectious diseases Collaboration agreement
2011-02-18 Faron Pharmaceuticals (Finland) Maruishi Pharmaceutical (Japan) Traumakine-program including FP-1201

licensing
development
commercialisation

Cardiovascular diseases Licensing agreement
2011-02-17 MediGene (Germany) Pierre Fabre Medicament (France) Veregen® ointment (made from the extract of green tea leaves - catechins) External genital warts

licensing
commercialisation
distribution

Infectious diseases - Gynecology Licensing agreement
2011-02-15 Evotec (Germany) ChemBridge (USA) hit identification platform

Collaboration

Collaboration agreement
2011-02-15 CIT (France) Stemina Biomarker Discovery (USA) devTOX® assay

Collaboration
Distribution

Distribution agreement
2011-02-15 Boehringer Ingelheim (Germany) Pfenex (USA) Pfenex Expression Technology ™ platform

licensing

Licensing agreement
2011-02-15 Invivoscribe Technologies (USA) Novartis (Switzerland) companion diagnostic test to identify FLT3 positive acute myeloid leukemia (AML) patients for specific use in connection with midostaurin (PKC412) FLT3 positive acute myeloid leukemia

development
commercialisation

Cancer Oncology Development agreement
2011-02-15 Grunenthal (Germany) Xention (UK) new drugs to treat chronic pain chronic pain

R&D

CNS diseases R&D agreement
2011-02-11 Jomaa Pharma (Germany) Medicines for Malaria Venture (MMV) (UK) fosmidomycin, as a component of non-artemisinin based combination therapy (NACT), for acute Plasmodium falciparum malaria malaria

development

Infectious diseases - Parasitic diseases Development agreement
2011-02-09 Boehringer Ingelheim (Germany) Elan (Ireland) antibody-based therapeutics undisclosed

Development
Manufacturing
Production

undisclosed Development agreement
2011-02-09 Circassia (UK) Airmid (USA) PAP-1 psoriasis - atopic dermatitis

development
commercialisation

Autoimmune diseases - Dermatological diseases Development agreement
2011-02-07 Medivir (Sweden) Janssen Pharmaceutica, a J&J company (USA) drugs based on the inhibition of the dengue NS3 protease activity dengue fever

R&D

development

commercialisation

Infectious diseases R&D agreement
2011-02-07 Debiopharm (Switzerland) Marina Biotech (USA) RNAi-based therapy bladder cancer

licensing
development
commercialisation

Cancer Oncology Licensing agreement
2011-02-03 Novasep (France) instrAction (Germany) purification of taxane-based active pharmaceutical ingredients (APIs) and intermediates

Development
Manufacturing
Production

Cancer - Oncology Development agreement
2011-02-01 Apeiron Biologics (Austria) Merck KGaA, , Merck Serono (Germany) hu14.18-IL2 pediatric neuroblastoma - melanoma

licensing

Cancer - Oncology Licensing agreement
2011-01-31 Newron (Italy) Merck Serono (Germany) pruvanserin and sarizotan CNS diseases

Licensing

CNS diseases Licensing agreement
2011-01-28 MDxHealth (Belgium) Pfizer (USA - NY) Newcastle University (UK) Cancer Research Technology Limited (CRT) UK biomarker predicting response to PF-01367338, drug candidate for PARP inhibition ovarian cancer breast cancer

R&D

development

Cancer - Oncology R&D agreement
2011-01-28 ALK (Denmark)Torii Pharmaceutical Co (Japan) house dust mite allergy immunotherapy products (Mitizak®, Alutard®) asthma - allergic rhinitis

development
commercialisation

Respiratory diseases - Inflammatory diseases - Allergic diseases Development agreement
2011-01-27 Bayer HealthCare (Germany) Zydus Cadila (India)

joint-venture

Gynecology - Diagnostic imaging - Cardiovascular diseases - Metabolic diseases - Cancer - Oncology Collaboration agreement